Evidence map›Paper›PMID 42603004›Full record

ArticleCureus2026

Tirofiban-Associated Thrombocytopenia: A Case Report.

Mohamed Hassan, Ayatullah Hegazy, Aya Majwal, Mahmoud Marashi, Talib Majwal

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed HassanIntensive Care Unit, Mediclinic City Hospital, Dubai, ARE.
Ayatullah HegazyCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, ARE.
Aya MajwalGraduate Medical Education, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, ARE.
Mahmoud MarashiDepartment of Hematology, Mediclinic City Hospital, Dubai, ARE.
Talib MajwalDepartment of Interventional Cardiology, Mediclinic City Hospital, Dubai, ARE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirofiban, a competitive inhibitor of glycoprotein IIb/IIIa receptors on platelet membranes that assist in aggregation, is widely used in high-risk acute coronary syndrome (ACS). We present a case of a 53-year-old man with acute coronary syndrome and triple vessel disease who developed thrombocytopenia after first exposure to tirofiban. He presented to our hospital after his left-sided chest pain had subsided, and he was started on tirofiban 0.15 µg/kg/min; baseline platelets were 264 × 10

Indexed as

acute coronary syndromepercutaneous coronary interventionthrombocytopeniatirofibantirofiban-associated thrombocytopenia

Identifiers

PMID42603004
PMCPMC13475774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.